Pediatr Blood Cancer by Baker, Charlotte et al.
Contribution of Sickle Cell Disease to the Pediatric Stroke 
Burden Among Hospital Discharges of African-Americans—
United States, 1997–2012
Charlotte Baker, DrPH1,*, Althea M. Grant, PhD1, Mary G. George, MD2, Scott D. Grosse, 
PhD1, and Thomas V. Adamkiewicz, MD3
1Division of Blood Disorders, National Center for Birth Defects and Developmental Disabilities, 
Centers for Disease Control and Prevention, Atlanta, Georgia
2Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease 
Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia
3Department of Family Medicine, Morehouse School of Medicine, Atlanta, Georgia
Abstract
Background—Approximately 10–20% of children with sickle cell disease (SCD) develop 
stroke, but few consistent national estimates of the stroke burden for children with SCD exist. The 
purpose of this study is to determine the proportion of diagnosed stroke among African-American 
pediatric discharges with and without SCD.
Procedure—Records for African-Americans aged 1–18 years in the Kids' Inpatient Database 
(KID) 1997–2012 with ≥1 ICD-9-CM diagnosis code for stroke were included. Data were 
weighted to provide national estimates. A total of 2,994 stroke cases among African-American 
children were identified. Diagnoses co-existing with ischemic or hemorrhagic stroke were 
frequency ranked separately.
Results—From 1997 through 2012, SCD was present in 24% of stroke discharges, with 89% 
being ischemic stroke. For hospital discharges of African-American children, SCD is the highest 
co-existing risk factor for ischemic stroke (29%). Stroke in children with SCD occurred 
predominantly in children aged 5–9 years, older than previously reported. The trend of stroke 
discharges significantly decreased for children with SCD from 1997 to 2012 for children aged 10–
14 years.
Conclusions—SCD is a leading risk factor to pediatric stroke in African-American children. 
Reducing the number of strokes among children with SCD would have a significant impact on the 
rate of strokes among African-American children. Preventative intervention may be modifying 
initial age of presentation of stroke in children with SCD.
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INTRODUCTION
Stroke affects an estimated 1.2–13 children per 100,000 population under the age of 18 each 
year in the United States of America.[1–4] It is the eighth leading cause of death for children 
1–18 years of age and children who survived may be left with disabilities such as changes to 
or difficulties with cognitive ability, senses, speech, behavior, and partial or complete 
paralysis.[5–7] Despite signs, symptoms, and known risk factors, the diagnosis of stroke is 
often delayed or missed in children as they may be misdiagnosed with other conditions that 
mimic the symptoms of stroke.[1]
Approximately 72,000–100,000 people in the United States are affected by SCD.[8] 
Because of newborn screening, we know that SCD occurs in approximately one in 365 
African-American births, making African-Americans the predominant group in the United 
States affected by the disease.[8]
Stroke is a leading cause of morbidity and mortality in children with SCD, especially in 
children with hemoglobin SS, the most common and severe form of SCD.[9] In a multi-
center prospective natural history study (CSSCD), 11% of patients with hemoglobin SS 
under the age of 20 years develop stroke, with a peak incidence of 1.02 per 100 person-years 
in children between the ages of 2 and 5 years.[10] Most strokes among children with SCD 
are ischemic, caused by a vasculopathy that leads to progressive stenosis and eventual 
catastrophic occlusion of the large arterial branches off the circle of Willis. Patients with 
SCD also can develop other forms of brain injury including the following: hemorrhagic 
strokes (older patients), transient ischemic attacks, compensatory abnormal small blood 
vessel growths (Moya Moya disease), silent infarctions, and progressive neurocognitive 
impairment.[9] Patients with other forms of SCD (e.g., hemoglobin SC, S Beta thalassemia
+, and S Beta thalassemia 0) also develop stroke and brain injuries, but these appear less 
frequent.[10]
There are few consistent national estimates of the proportion of children with SCD who 
have a stroke. Further confounding the issue is the fact that some estimates include only 
ischemic strokes or those with infarction, whereas others include both ischemic and 
hemorrhagic strokes.[11–13] Stroke is an important cause of cognitive decline in patients 
with SCD.[14] Understanding the burden of disease and disability due to stroke among those 
with SCD is important for both clinicians and policy makers.
The epidemiology of stroke and SCD is understudied in the African-American population, 
and most current studies in this area focus on adults with SCD. The purpose of this study 
was to determine the proportion of SCD among the African-American pediatric population 
with stroke.
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METHODS
The present study utilized the Healthcare Cost and Utilization Project (HCUP) Kids' 
Inpatient Database (KID). The KID is among a family of databases and software tools 
developed as part HCUP, sponsored by the Agency for Healthcare Research and Quality 
(AHRQ) in partnership with state-level data-collection organizations to provide national 
estimates of inpatient care.[15] KID is an administrative all-payer inpatient care database 
made of a stratified sample of pediatric discharges from community hospitals in the United 
States and includes weights to calculate national estimates. Since 1997, data for KID have 
been collected and released every three years and each release includes a single year of data. 
We utilized each available year of data—1997, 2000, 2003, 2006, 2009, and 2012—for a 
total of 6 years of data. KID includes information on discharges of patients 20 years of age 
and younger for years 2000–2012 and 18 years of age and younger for 1997.
We selected discharges where the race was recorded as black (which excludes those of 
Hispanic ethnicity) and where age at discharge was ≥1 year of age and ≤18 years of age. 
One year of age was chosen as the lower bound to minimize the inclusion of perinatal stroke 
in the study population and to be consistent across all years of data. Age was divided into 
four categories: 1–4 years, 5–9 years, 10–14 years, and 15–18 years to be consistent with 
existing literature. Discharges were included whether they were for patients alive or dead at 
time of discharge.
For each discharge, at least one ischemic (ICD-9-CM 433.01, 433.11, 433.21, 433.31, 
433.81, 433.91, 434.01, 434.11, 434.91, 436) and/or hemorrhagic stroke (430, 431) ICD-9-
CM code had to be present in at least one of the 15 available diagnosis fields. For analyses 
considering SCD status, ICD-9-CM codes distinguishing the presence of SCD (282.60–
282.64, 282.68–282.69, 282.41–282.42) had to be present in at least one of the 15 available 
standard diagnosis fields.
To identify the presence of co-existing medical conditions that are known risk factors for 
pediatric stroke, we modified a method originally from Fullerton et al.[16] and modified by 
Lo et al.[5] We searched all available diagnosis fields in a secondary data source for ICD-9-
CM codes representing known pediatric stroke risk factors and then frequency ranked the 
results. In addition, we removed ischemic stroke diagnoses without infarction (433.x0, 
434.x0), used the individual codes for each type of SCD (282.60–282.64, 282.68, and 
282.69) instead of the overarching code (282.6), and added codes for sickle beta thalassemia 
(282.41 and 282.42). This modification was made to achieve better accuracy in identifying 
those with stroke and SCD (Table I).
All data analyses were conducted using the SAS (versions 9.2 and 9.3; SAS Institute Inc., 
Cary, NC) survey procedures. Using the HCUP provided weights, strata, and clusters, we 
calculated national estimates for frequencies of discharge demographics, SCD status, and 
stroke type. We utilized the F test to determine if there were differences in the proportions 
within each category (overall African-American children, African-American children with 
SCD, and African-American children without SCD) for age, for sex, and for age group. An 
F test was also used to determine if there were differences in the distribution of proportions 
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of age, sex, and age group for those with SCD compared to those without SCD (between 
group differences). The P-value associated with the F-value from the F test was used to 
determine whether statistically significant differences were present for these within group 
and between group analyses. A P-value of <0.05 was used as the cutoff point of statistical 
significance. We assessed for trends in the proportions of stroke among children with SCD 
from 1997 to 2012 using linear regression.
Weighted frequencies of 10 or lower were not presented in accordance with HCUP policies. 
All numbers reported in this manuscript are weighted and are rounded up to whole numbers 
to be consistent with HCUP reporting.
RESULTS
There were 1.8 million discharges aged 1–18 years with race identified as African-American 
in the HCUP KID 1997–2012 after weighting. Of the 1.8 million weighted discharges, 2,994 
discharges had at least one stroke diagnosis code present. Of the 2,994 discharges with a 
stroke code, 703 (weighted) also had a diagnosis code for SCD. We found that for all 
African-American pediatric stroke discharges, regardless of SCD status, and for African-
American pediatric stroke discharges without SCD, the highest proportion of discharges 
occurred among children 15–18 years of age, followed by children aged 10–14 (P < 0.0001). 
For African-American pediatric stroke discharges with SCD, however, the highest 
proportion of discharges occurred among children 5–9 years of age followed by children 10–
14 years of age (P < 0.0001). In a comparison of the group with SCD and the group without 
SCD, we found the difference in the distributions of age to be significant (P < 0.0001). We 
found no significant difference in the distribution of stroke by sex for all African-American 
stroke discharges (P 0.2747) or in a comparison of the group with SCD and the group 
without SCD (P 0.3762) (Fig. 1).
Of the 2,994 total discharges among all African-American pediatric discharges with stroke 
in the study period, 1,170 (39.1%) had at least one diagnosis code for hemorrhagic stroke 
and 1,880 (62.8%) had at least one diagnosis code for ischemic stroke. There were 57 
discharges (1.9%) that had diagnosis codes for both hemorrhagic stroke and ischemic stroke. 
Of the hemorrhagic stroke discharges, 486 (16.2%) had diagnosis codes for subarachnoid 
hemorrhage and 727 (24.3%) had diagnosis codes for intracerebral hemorrhage. There were 
42 discharges (3.6%) that had diagnosis codes for both subarachnoid and intracerebral 
hemorrhage. Stroke discharges that also had diagnosis codes for SCD (703) represented 24% 
of total stroke discharges. The majority of SCD and stroke discharges had codes for 
ischemic stroke (89%) (P < 0.0001); the same was also true for stroke discharges without 
SCD (55%) (P < 0.0001) (Table II).
After 1997, there was a modest but statistically significant reduction in the proportion of all 
stroke discharges among African-American children associated with SCD (Fig. 2; Table III). 
The reduction in SCD-related stroke discharges was restricted to ischemic stroke. There was 
no reduction in SCD-related stroke at ages 1–4 years and almost no change at 15–19 years.
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After frequency ranking co-existing pediatric stroke risk factors, we found that for ischemic 
stroke discharges among all African-American pediatric discharges with stroke, SCD was 
the most common co-existing risk factor (present in 33.8% of ischemic discharges), 
followed by congenital heart disease (19.2%), sepsis/bacteremia (16.4%), head trauma 
(15.2%), and meningitis/encephalitis (13.6%). For hemorrhagic stroke discharges among all 
African-American pediatric discharges with stroke, congenital heart disease was the most 
common co-existing risk factor (24.4%), followed by arrhythmias (18.4%), sepsis/
bacteremia (16.2%), coagulation defects (13.2%), and arteriovenous malformation (12.7%). 
SCD frequency ranked ninth among co-existing diagnoses (8.0%) for hemorrhagic stroke 
discharges (Table IV).
DISCUSSION
Children with SCD, prior to a first stroke, develop increased blood flow in large cerebral 
vessels. This can be measured by noninvasive Transcranial Doppler (TCD) ultrasound, and 
identify an individual at risk for stroke. The Stroke Prevention in Sickle Cell Anemia or 
STOP trial found that chronic transfusion could prevent first stroke in children with SCD at 
high risk of stroke as determined by TCD screening. This strategy reduced the untreated risk 
of stroke, which was 10%, by 90%.[17] Since the first STOP trial, the National Heart Lung 
and Blood Institute has recommended TCD screening for children 2–16 years of age. The 
Optimizing Primary Stroke Prevention in Sickle Cell Anemia or STOP two Trial found that 
alternative long-term solutions are needed to maintain normal blood flow velocity after 
cessation of chronic transfusions.[18] Existing alternatives include stem cell transplantation, 
bone marrow transplantation, and oral hydroxyurea.[19–22]
Two recent studies of pediatric stroke hospitalizations among all children in the United 
States identified SCD as a risk factor for stroke. First, Fullerton et al. reported that compared 
to white children, African-American children are at an increased risk of stroke and the 
increased risk remained even when controlling for the presence of SCD.[16] Second, Lo et 
al. found SCD to be the fifth most frequent risk factor recorded for children with ischemic 
stroke and the 15th most frequent among children with hemorrhagic stroke but did not 
stratify by race/ethnicity.[5]
Three other studies examined recent trends in SCD as a comorbid diagnosis with pediatric 
stroke hospital diagnoses spanning the period before and after TCD screening, as well as 
hydroxyurea licensure in patients with SCD. George et al. found that from 1995–1996 to 
2007–2008 the frequency of SCD diagnoses associated with ischemic stroke hospitalizations 
among children ages 5–14 years decreased by more than half but no change for hemorrhagic 
stroke was reported.[23] Ovbiagele and Adams also found a decrease in the frequency of 
SCD diagnoses among pediatric stroke discharges during the period from 1997 to 2006 that 
was concentrated among discharges with ischemic stroke.[24] McCavit et al. calculated 
estimated rates of stroke using two separate HCUP data sets: Nationwide Inpatient Sample 
(NIS) (an administrative all-payer sample of community hospitals in the United States) and 
the KID. [25] Rates of stroke significantly decreased between 1997 (0.54 and 0.51 per 100 
admissions per year, respectively) and 2009 (0.24 and 0.28 per 100 person years).[25] All 
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three studies suggest effective implementation of stroke prevention strategies in patients 
with SCD.
In the current study, approximately 24% of all African-American pediatric discharges with 
an ICD code for a stroke diagnosis also have a diagnosis code for SCD. Ischemic strokes 
were more common than hemorrhagic strokes among African-American pediatric stroke 
discharges. This difference was more pronounced for discharges with SCD compared to 
those without SCD (89% vs. 55%). As SCD is a known risk factor for ischemic stroke, this 
distribution was not unexpected.
The frequency of stroke discharges differed by age groups and SCD status. It was interesting 
to note that stroke discharges for children with SCD occurred predominantly in the 5–9 age 
group, Similarly, McCavit found that the median age at stroke was 8 years, with an inter 
quartile range between 5 and 13 years.[25] Stroke discharges for children without SCD 
occurred predominantly in the 15–18 age group.[26] The reason for these age differences 
was not assessed in this study, but most likely represents the differences in the mechanisms 
of disease. Stroke in patients with SCD appeared at an older age than previously reported in 
the CSSCD.[10]
The contribution of SCD to the pediatric stroke burden among discharges of African-
American children is much higher than that reported previously for the general pediatric 
population by Lo et al. We found that among discharges reflected in HCUP KID, SCD was 
the most common co-existing risk factor for ischemic stroke discharges and the ninth most 
common co-existing risk factor for hemorrhagic stroke for children discharged during the 
study time period. This was consistent with the results from Fullerton et al. that also found 
the rate among African-American children to be higher and also that SCD was not the sole 
cause of strokes among African-American children.[16] It is important to continue to study 
this population separately to draw implications for treatment and prevention of pediatric 
stroke.
Mechanisms of stroke in children with SCD include disturbances in blood flow, perturbed 
red blood cell/endothelial wall interaction with subsequent damage, pro-inflammatory and 
pro-coagulant responses.[9] Known prior risk factors include high arterial blood velocity, 
transient ischemic attacks, silent infarction, acute chest syndrome, high blood pressure, or 
nocturnal hypoxia.[9] Although children with stroke in general are at increased risk for 
hereditary thrombophilias,[27] this has not been extensively reported in patients with SCD. 
Individuals with SCD and silent cerebral infarction[28] or stroke[29] were found to have 
decreased tissue plasminogen activator antigen,[28] ADAMTS-13,[28] and increased D-
dimers [28,29] compared to controls. Chronic transfusion in children with SCD not only 
decreases percent of sickle cells, but also appears to correct SCD induced pro-coagulant 
marker profile.[30] Examination of such possible contributing factors requires detailed, 
accurate information, often not readily available in an administrative data set, and were not 
examined in the present study.
The recent study of children and adults with SCD and stroke by Ovbiagele et al. utilized 
different methodology than the present study.[24] That study utilized the HCUP NIS and 
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found a decrease in the frequency of SCD diagnoses among pediatric stroke discharges 
during the period from 1997 to 2006 that was concentrated among discharges with ischemic 
stroke.[24] Similar to the present study, Ovbiagele found that the proportion of ischemic 
stroke was higher than the proportion of hemorrhagic stroke for discharges with SCD.[24] 
The downside to using NIS to study children is that the hospital sample changes each year 
and may or may not include the same number of children and children's hospitals, unlike the 
KID database utilized in the present study. Consistent with the findings of George et al., [23] 
the reduction in SCD-related stroke hospitalizations was concentrated in the 5–14 years age 
group. The decrease was much larger in the 10–14 years age group than the 5–9 years age 
group and only the former decrease was significantly different from zero.
LIMITATIONS
The number of states varied by year of data collection and the analyses include information 
only from states that report race information. This limitation has been previously reported in 
studies that show up to 20% of race and ethnicity data is missing not at random inHCUP, a 
concern of great importancewhen considering the statistical validity of results involving race 
and ethnicity.[23,31,32] An average of 20.6% of discharges (range 8.2–28.1%) was 
excluded from the present study due to missing race and ethnicity information. Although the 
use of the provided weights helped adjust for this to a degree, there is also the possibility 
that our estimate of stroke cases and SCD cases is inaccurate.
The use of secondary data, including administrative data, is advantageous for studying rare 
conditions when considering both the amount of time needed to gather a significant number 
of observations in a primary data study, particularly one that is nationally representative. 
However, the variation in methodology also increases the chance for misclassification bias. 
The misdiagnosis or inaccurate coding of stroke could contribute to an under or 
overestimation of stroke events or discharges. Stroke diagnosis in adults, based on Joint 
Commission and the Centers for Medicare and Medicaid criteria,[33] have positive 
predictive value (PPV) above 90%.[34] PPV for ischemic stroke in children varies between 
40 and 74% for outpatients and inpatients, respectively, when these were compared to 
imaging report text searches.[35] In that study, 57% of diagnosis of stroke was missed by 
ICD9/CP code registry search.[35] For a single sickle cell diagnosis, PPV varies between 83 
and 96% for outpatients and inpatients, respectively, when compared to newborn screening.
[36] With repeated diagnosis, PPV and specificity increase, but sensitivity decreases.[36]
We likely underestimated the number of stroke discharges and stroke discharges with SCD 
due to changes in the available variables used to calculate age. In 2012, variables that would 
allow for the selection of children under the age of 1 but greater than 28 days were 
unavailable for HCUP KID. Thus, the age of 1 year was used as the cutoff for inclusion in 
all years and relevant strokes for children under the age of 1 were not included.
One limitation of this study is the lack of a comparison population affected by SCD. 
Hispanic children would be an optimal group to use due to the rising population in the 
United States and the fact that one out of every 16,305 Hispanic births is affected by SCD.
[8] It was not possible to do so in this study due to the small number of Hispanic children 
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with SCD and stroke (32 hospitalizations after weighting). Future studies would benefit 
from the utilization of data with a larger Hispanic population.
A final limitation is that the analysis did not include discharges with diagnoses of SCD for 
which stroke diagnoses were not recorded. As is true of previous analyses, this analysis was 
limited to SCD as a comorbid condition and did not assess the frequency of stroke among 
children hospitalized with SCD. However, such estimates were recently published. This 
study complements McCavit et al.'s study, by placing SCD in the context of stroke burden in 
the general African-American population.population.[25]
As with prior studies, we used an administrative data set of hospital discharges with no 
individual record linkages. McCavit included stroke diagnosis if it was listed first.[25] 
Because we included any stroke diagnosis listed, our data likely included first stroke, as well 
as repeat visits by individuals with a prior stroke, representing a measure of prevalence. 
Trends appeared more modest in the current study possibly because these trends reflect 
overall burden of stroke rather than acute stroke, as defined by a first diagnosis. The use of a 
large multi-year secondary data source allowed for the identification of rare outcomes such 
as stroke and SCD among a nationally representative group of African-American discharges 
in the United States. This study fills some gaps in knowledge of stroke and SCD in the 
African-American population such as how large of a contribution SCD makes to stroke 
among African-American children and adolescents compared to the general pediatric 
population. This study demonstrates the value of looking at the relationship between stroke 
and SCD using a population-based approach as well as the need for further studies 
especially on the age distribution of stroke considering SCD status and the trend of stroke 
among SCD patients before and after the introduction of TCD screening.
Stroke among African-American children is to a degree preventable particularly with the use 
of methods such as TCD screening and chronic transfusion. Because the contribution of 
SCD to the stroke burden in African-American children is significant, African-American 
children with SCD should be targeted for stroke prevention, intervention, and further study.
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Fig. 1. 
African-American pediatric stroke discharges by age group and SCD status from 6 years of 
HCUP KID 1997–2012. The highest proportion of discharges for all children (N = 2,994) 
and for those without SCD (N = 2,291) occurred among children 15–18 years of age. For 
children with SCD (N = 703), the highest proportion of discharges occurred among children 
aged 5–9. SCD, sickle cell disease; HCUP, Healthcare Cost and Utilization Project; KID, 
Kids' Inpatient Database.
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Fig. 2. 
Trend of pediatric stroke discharges among African-American children with SCD by age 
from six years of HCUP KID 1997–2012. The percentage of discharges for stroke among 
African-American children with SCD declined significantly for those aged 10–14 years of 
age from 1997 through 2012. SCD, sickle cell disease; HCUP, healthcare cost and 
utilization project; KID, kids' inpatient database.
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TABLE I
ICD-9-CM Codes Used to Identify Co-Existing Pediatric Stroke Risk Factors
Congenital heart disease 648.5, 745.xx, 746.xx, 747.xx
Cardiomyopathy 425.x
Valvular heart disease 424.0–424.3
Arrhythmias 427.xx
Cardiac arrest 427.5
Aneurysm 437.3
Arteriovenous malformations 747.81, 228.02
Moyamoya disease 437.5
Brain tumors (benign and malignant) 191.x, 225.x, 239.6, 198.3, 237.5, 237.6
Dehydration 276.5x, 775.5
Coagulation defects 286.x, 790.92
Other diseases of blood and blood forming organs 
hypercoaguable states
289.8, 289.81, 289.82
Purpura and other hemorrhagic conditions 287.x
Leukemia, lymphotic 204.x
Leukemia 205.x, 206.x, 207.x, 208.x
Lymphoma 200.xx–203.xx
SCD 282.60–282.64, 282.68, 282.69, 282.41, 282.42
HIV/AIDS 42
Chicken pox/varicella 52
Meningitis/encephalitis 003.21, 013.x, 036.x, 047.x, 048.x, 049.x, 053.0–054.1x, 054.3, 054.72, 056.01, 
062.x, 064, 066.2, 063.x, 072.1–072.2, 090.42, 091.81, 094.2, 094.81, 098.82, 
100.81, 112.83, 114.2, 115.01, 115.11, 115.91, 130.0, 136.2, 139.0, 320.xx–
322.xx, 323.xx
Endocarditis 036.42, 074.22, 098.84, 093.20–24, 112.81, 115.04, 115.14, 115.94, 391.1, 421.x, 
424.91
Sepsis/Bacteremia 038.xx, 790.7, 771.8x
Autoimmune disease 136.1, 437.4, 446.x, 447.6, 710.x, 714.xx, 795.79
Migraine 346.xx
Head trauma 850–854.1, 800–804.9
Birth trauma 767.x
Cocaine/amphetamine 304.2, 305.6, 760.75, 304.4, 305.7
Hypertension 401.x, 404.x, 405.x
Diabetes 250
Lipid abnormalities 272.x
Obesity 278.00–01
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TABLE II
African-American Pediatric Stroke Discharges by SCD Status and Stroke Type in Six Years of HCUP KID 
1997–2012*
National estimate % P
Total stroke 2,994 <.0001
 Subarachnoid hemorrhage 486 16.2
 Intracerebral hemorrhage 727 24.3
 Ischemic stroke 1,880 62.8
SCD 703 23.5 <.0001
 Subarachnoid hemorrhage 45 10
 Intracerebral hemorrhage 50 8.5
 Ischemic stroke 623 88.7
No SCD 2292 76.5 <.0001
 Subarachnoid hemorrhage 441 19.2
 Intracerebral hemorrhage 678 29.6
 Ischemic stroke 1257 54.8
SCD, sickle cell disease; HCUP, healthcare cost and utilization project; KID, kids' inpatient database;
*Weighted national estimates do not sum to total because of rounding and because of overlapping stroke diagnoses in 57 discharges (13 with sickle 
cell disease overlap, 44 without sickle cell disease overlap). There are overlapping hemorrhagic stroke diagnoses in 42 discharges (2 with sickle 
cell disease overlap, 40 without sickle cell disease overlap).
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TABLE III
Results of Trend Analysis for Stroke Among Discharges With SCD by Age in HCUP KID 1997–2012
Parameter estimate 95% CI
All stroke with SCD −0.54562 −0.91286, −0.17839
All stroke with SCD—1–4 years of age 0.06851 −1.12819, 1.26520
All stroke with SCD—5–9 years of age −0.43234 −2.38594, 1.52126
All stroke with SCD—10–14 years of age −1.45378 −2.28326, −0.62431
All stroke with SCD—15–18 years of age −0.30807 −1.5226, 0.63612
Ischemic stroke with SCD −0.52736 −0.81455, −0.24017
Ischemic stroke with SCD—1–4 years of age 0.43815 −1.41568, 2.29197
Ischemic stroke with SCD—5–9 years of age −0.71007 −4.36199, 2.94185
Ischemic stroke with SCD—10–14 years of age −2.15424 −4.33152, 0.02304
Ischemic stroke with SCD—15–18 years of age −0.24319 −1.47389, 0.98751
SCD, Sickle cell disease; HCUP, healthcare cost and utilization project; KID, kids' inpatient database.
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TABLE IV
Proportion Distribution of Pediatric Stroke by Co-Existing Risk Factors Among African–American 
Discharges in Six Years of HCUP KID 1997–2012
N %
Ischemic stroke
 SCD 635 33.8
 Congenital heart disease 361 19.2
 Sepsis/Bacteremia 309 16.4
 Head trauma 285 15.2
 Meningitis/Encephalitis 256 13.6
 Arrhythmias 256 13.6
 Hypertension 177 9.4
 Coagulation defects 155 8.2
 Autoimmune disorders 131 7
 Dehydration 125 6.6
Hemorrhagic stroke
 Congenital heart disease 286 24.4
 Arrhythmias 215 18.4
 Sepsis/Bacteremia 190 16.2
 Coagulation defects 155 13.2
 Arteriovenous malformation 149 12.7
 Hypertension 143 12.2
 Meningitis encephalitis 113 9.7
 Brain tumors 105 9
 SCD 94 8
 Purpura and other hemorrhagic conditions 90 7.7
SCD, sickle cell disease; HCUP, healthcare cost and utilization project; KID, kids' inpatient database.
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